Scarica l'app Stockscreener
1.51
2.03%
0.03
Dopo l'orario di chiusura:
1.55
0.04
+2.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.48
Aprire:
$1.48
Volume 24 ore:
2.68M
Relative Volume:
3.03
Capitalizzazione di mercato:
$103.24M
Reddito:
$593.00K
Utile/perdita netta:
$-45.85M
Rapporto P/E:
-2.1996
EPS:
-0.6865
Flusso di cassa netto:
$-37.97M
1 W Prestazione:
-22.16%
1M Prestazione:
-11.70%
6M Prestazione:
-25.98%
1 anno Prestazione:
-54.93%
Intervallo 1D:
$1.465
$1.60
Intervallo di 1 settimana:
$1.40
$1.98
Portata 52W:
$1.40
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Nome
Cardiff Oncology Inc
Settore
Industria
Telefono
858-952-7570
Indirizzo
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.51 | 101.19M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
425.09 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
602.92 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.17 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.12 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.31 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | Noble Capital Markets | Outperform |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-06-24 | Iniziato | Jefferies | Hold |
| 2024-09-06 | Iniziato | Craig Hallum | Buy |
| 2022-01-05 | Iniziato | William Blair | Outperform |
| 2021-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2021-08-09 | Ripresa | Maxim Group | Buy |
| 2020-10-22 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-08 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Cardiff Oncology (CRDF) Reports Promising Phase 2 Results for On - GuruFocus
Cardiff Oncology reports positive phase 2 trial results for onvansertib - Investing.com
Cardiff Oncology Announces Presentation Of Positive Results From Its Randomized, Controlled Phase 2 Trial Of Onvansertib In First-Line RAS-Mutated mCRC At The 2026 ASCO Annual Meeting - TradingView
New colorectal cancer drug combo shows 72% response in trial - Stock Titan
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Clinical-stage biotech CEO in Jefferies health conference fireside chat - Stock Titan
CRDF Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
CRDF Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Cardiff Oncology (CRDF) Files Lawsuit Against Nerviano Medical S - GuruFocus
TD Cowen Downgrades Cardiff Oncology to Hold From Buy - Moomoo
H.C. Wainwright cuts Cardiff Oncology stock rating on license termination By Investing.com - Investing.com Canada
TD Cowen downgrades Cardiff Oncology stock rating on license dispute By Investing.com - Investing.com Canada
Cardiff Oncology, Inc. 8-K Filing Details for May 27, 2026: Company Information, NASDAQ Listing, and Key Disclosures - Minichart
Cardiff OncologyNms Informs Cardiff Oncology Of Agreement Termination On May 27, 2026 - TradingView
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
Cardiff Oncology 1Q Loss/Shr 18c >CRDF - Moomoo
CRDF Technical Analysis | Trend, Signals & Chart Patterns | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
CRDF: First Quarter 2026 Results - Zacks Small Cap Research
Cardiff Oncology to host webcast on cancer trial data By Investing.com - Investing.com South Africa
Cardiff Oncology to host webcast on cancer trial data - Investing.com UK
New colorectal cancer trial data heads to ASCO, investor webcast June 3 - Stock Titan
Cardiff Oncology Announces Webcast to Discuss Updated Phase - GlobeNewswire
Cardiff Oncology sues Nerviano as analyst backs Onvansertib defense - MSN
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense - Benzinga
Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Cardiff Oncology Files Lawsuit Over Onvansertib Patent Rights - TipRanks
Cardiff Oncology, Inc. (CRDF) has filed documents with the U.S. Securities and Exchange Commission (SEC), disclosing that it has initiated a lawsuit against Nerviano Medical Sciences, accusing the latter of breaching the licensing agreement regarding the in - Bitget
Is Cardiff Oncology (CRDF) 5.1% Undervalued After Q1 2026 Earnin - GuruFocus
A Quick Look at Today's Ratings for Cardiff Oncology(CRDF.US), With a Forecast Between $6 to $10 - Moomoo
Cardiff Oncology (CRDF) Reports Positive Trial Data and Leadersh - GuruFocus
Cardiff Oncology (CRDF) Secures Funding Through 1Q27 - GuruFocus
Cardiff Oncology Q1 net loss narrows as operating expenses fall - TradingView
Cardiff Oncology earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update - The Manila Times
Cardiff Oncology: Q1 Earnings Snapshot - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) details Q1 2026 loss and Phase 3 plans - Stock Titan
FDA meeting maps Phase 3 test of Cardiff's colorectal cancer drug - Stock Titan
Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiff Oncology (NASDAQ: CRDF) posts Q1 loss, warns on cash and details onvansertib data - Stock Titan
Cardiff Oncology, Inc.Common Stock (NQ: CRDF - FinancialContent
CRDF Stock Price, Quote & Chart | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
TradingKey - TradingKey
CRDF Technical Analysis & Stock Price Forecast - Intellectia AI
Cardiff Oncology (CRDF) to Release Earnings on Thursday - MarketBeat
MSN Money - MSN
Cardiff Oncology Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Cardiff Oncology Inc Azioni (CRDF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):